Jeremy Bender
Chief Executive Officer chez DAY ONE BIOPHARMACEUTICALS, INC.
Fortune : 29 M $ au 31/03/2024
Profil
Jeremy Bender is currently the Chief Executive Officer at DOT Therapeutics-2, Inc., the President, Chief Executive Officer & Director at Day One Biopharmaceuticals, Inc., a Non-Executive Director at Mereo BioPharma Group Plc, and a Director at Fusion Pharmaceuticals, Inc. Previously, he held positions as the Vice President-Corporate Development at Gilead Sciences, Inc. from 2018 to 2020, the Vice President-Corporate Development at Allos Therapeutics, Inc. from 2006 to 2012, the Chief Business Officer at Sutro Biopharma, Inc. from 2012 to 2015, and the Chief Operating Officer at Tizona Therapeutics, Inc. from 2015 to 2018.
Dr. Bender has an undergraduate degree from Stanford University, a doctorate from The University of Colorado, and an MBA from MIT Sloan School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/03/2024 | 1 765 537 ( 2,02% ) | 29 M $ | 31/03/2024 | |
| 16/10/2023 | 0 ( -.--% ) | - $ | 31/03/2024 | |
| 08/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Jeremy Bender
| Sociétés | Poste | Début |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Director/Board Member | 01/10/2020 |
| DAY ONE BIOPHARMACEUTICALS, INC. | Chief Executive Officer | 01/09/2020 |
| FUSN PHAR | Director/Board Member | 16/10/2023 |
DOT Therapeutics-2, Inc.
 DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Chief Executive Officer | - |
Anciens postes connus de Jeremy Bender
| Sociétés | Poste | Fin |
|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/09/2020 |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Chief Operating Officer | 01/03/2018 |
| SUTRO BIOPHARMA, INC. | Corporate Officer/Principal | 01/07/2015 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | 01/09/2012 |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Formation de Jeremy Bender
| Stanford University | Undergraduate Degree |
| The University of Colorado | Doctorate Degree |
| MIT Sloan School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| SUTRO BIOPHARMA, INC. | Health Technology |
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| FUSN PHAR | Health Technology |
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Health Technology |
